[Morphologic findings during regression of heart hypertrophy]

Zeitschrift Fur Kardiologie
|January 1, 1985
PubMed

Insights

Cardiac hypertrophy, or heart muscle enlargement, can regress when the cause is removed. However, factors like fibrosis can lead to irreversible changes, impacting heart weight recovery.

Area of Science:

  • Cardiovascular Physiology
  • Cell Biology
  • Pathology

Context:

  • The heart adapts to increased workload through hypertrophy, involving changes in cardiac muscle cells, organelles, and interstitial tissue.
  • Different types of hypertrophy (training, volume, pressure overload) exhibit distinct morphological and biochemical adaptations.
  • Hypertrophy is generally reversible upon removal of the causative stimulus.

Purpose:

  • To investigate the reversibility of cardiac hypertrophy under various conditions, including training, pressure overload, and after valve replacement.
  • To elucidate the cellular and molecular mechanisms underlying the regression of cardiac hypertrophy.
  • To identify factors that may contribute to irreversible hypertrophy.

Summary:

  • Training-induced cardiac hypertrophy in rats showed significant regression (80%) within 14 days, with normalization of cell size and organelle ratios, suggesting reduced synthesis is key.
  • Pressure overload hypertrophy regression involves muscle cell size reduction but not interstitial collagen decrease; studies in pigs and hypertensive rats indicate complex regression patterns.
  • Irreversible hypertrophy in patients post-valve replacement is linked to recurrent infarction or fibrosis, highlighting the impact of underlying pathology on regression potential.

Impact:

  • Understanding hypertrophy regression mechanisms can inform therapeutic strategies for heart conditions.
  • Identifying factors limiting regression is crucial for managing heart failure and improving patient outcomes.
  • This research contributes to the knowledge of cardiac remodeling and its potential for reversal.

Related Concept Videos

Development of the Heart01:27

Development of the Heart

The development of the human heart, a crucial organ, commences from the mesoderm on the 18th or 19th day after fertilization. This process initiates in the cardiogenic area, a group of mesodermal cells at the embryo's head end, which evolves into elongated strands known as cardiogenic cords. These cords undergo a transformation to form hollow-centered endocardial tubes.
As the embryo undergoes lateral folding, these paired tubes approach each other, merging into a single primitive heart tube by...
Mitral Stenosis II: Clinical features and Diagnostic Tests01:23

Mitral Stenosis II: Clinical features and Diagnostic Tests

Mitral stenosis is a heart condition in which the mitral valve, which allows blood to flow from the left atrium to the left ventricle, becomes narrowed or stenotic. This narrowing hinders blood flow and leads to clinical symptoms requiring specific medical evaluations and management strategies. The following overview outlines the clinical symptoms, assessments, diagnostic findings, prevention methods, and treatments for mitral stenosis.Clinical ManifestationsDyspnea (shortness of breath): This...
Aortic Regurgitation II: Clinical Features and Diagnostic Tests01:22

Aortic Regurgitation II: Clinical Features and Diagnostic Tests

Aortic valve regurgitation (AR) occurs when the aortic valve fails to close properly, allowing blood to flow backward from the aorta into the left ventricle. This backflow can result in two distinct clinical presentations: acute and chronic AR, each characterized by its own set of symptoms and physical findings.Acute Aortic RegurgitationAcute AR presents with a sudden onset of severe symptoms. Patients typically experience profound dyspnea (shortness of breath), chest pain, and signs of left...
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
Cellular Adaptation II: Hypertrophy01:26

Cellular Adaptation II: Hypertrophy

Hypertrophy is the increase in the size of individual cells, resulting in the enlargement of a tissue or organ. Unlike hyperplasia, which involves an increase in cell number, hypertrophy is characterized by an increase in cell volume. This process often occurs in response to higher functional demand or hormonal stimulation, leading to the production of more structural proteins and organelles, thereby enhancing the cells' work capacity.There are two primary types of hypertrophy: physiological...